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This is confirmed by another study which 
demonstrated that the distribution of pre-
ventive interventions spanned the full range 
of cost-effectiveness results and that the 
majority of preventive interventions im-
proved outcomes, but also increased costs 
[5]. Therefore, although prevention is more 
cost-effective than a curative approach at ag-
gregate level, this may not necessarily be the 
case when comparing specific preventive and 
curative interventions.
METHODOLOGY
When assessing the cost-effectiveness of 
prevention, current techniques of econom-
ic evaluation may not be fully adapted to 
compute the economic and health impact of 
preventive interventions [2,6,7]. Particular 
methodological limitations arise, for exam-
ple, from:
 - the definition of the preventive inter-
vention and the comparator (i.e., the re-
cipients of the intervention, the setting in 
which the intervention is delivered, the 
various activities that make up the inter-
vention, etc.);
 - the need to estimate long-term costs and 
outcomes;
 - the use and validity of decision-analytic 
modeling approaches; 
 - the use of disease-specific rather than ge-
neric outcome measures;
 - the inclusion of benefits beyond those 
measured by traditional clinical outcome 
measures such as quality-adjusted life 
years;
 - the economic and health impact of the 
intervention on individuals other than the 
user of the intervention;
 - the inclusion of unrelated health care costs 
in life years gained through prevention.
As a result, economic evaluations may under-
estimate or over-estimate the cost-effective-
ness of preventive interventions [6].
COST-EFFECTIVENESS
When focusing on the burden of diseases 
attributable to specific risk factors, the lit-
erature argues that a substantial part of the 
economic and clinical burden of such dis-
eases can be averted by means of preven-
tion [2]. It is then implicitly assumed that 
prevention is cost-effective. A recent study 
measured the global burden of disease and 
assessed the cost-effectiveness of preventive 
interventions [3]. The authors observed that 
the majority of preventive interventions are 
cost-effective, but that these preventive in-
terventions do not always target the diseases 
with the highest burden. When comparing 
the proportion of economic evaluations fo-
cusing on a specific disease and the share of 
the global burden made up by that disease, 
the authors concluded that interventions that 
prevent infectious diseases and cancers are 
over-represented and that interventions that 
prevent mental and behavioral diseases and 
diseases of the respiratory system are under-
represented.
Prevention is not by definition cost-effective. 
Another study carried out an aggregate anal-
ysis of 231 economic evaluations reporting 
data about 608 incremental cost-effective-
ness ratios of pharmaceutical interventions 
published between 2000 and 2007 [4]. Of 
these economic evaluations, 7% related to 
preventive interventions and 93% to curative 
interventions. The authors found that preven-
tion was more cost-effective than a curative 
approach: preventive interventions had a 
significantly lower median ratio of 6,255 € 
per quality-adjusted life year than curative 
interventions (12,917 € per quality-adjusted 
life year; p = 0.002). Nevertheless, the cost-
effectiveness of preventive interventions var-
ied substantially and there were many cases 
where a particular curative intervention was 
more cost-effective than a specific preventive 
intervention.
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DECISION MAKING
The question of the cost-effectiveness of 
prevention is complicated by the decision 
making process. On the one hand, decision 
makers sometimes argue that cost-effec-
tiveness should not play a role in the choice 
to implement public health interventions 
such as screening for newborns [7]. On 
the other hand, decision makers sometimes 
promote prevention as a means to save 
health care costs, thereby holding preven-
tion to a higher standard than other health 
care interventions [6]. For instance, the ag-
gregate analysis of economic evaluations 
(cfr. supra) showed that 41% of preventive 
interventions saved money (and were more 
effective) than the comparator, but that 
59% of preventive interventions increased 
costs (and improved outcomes) [4]. Finally, 
a similar analysis of the cost-effectiveness 
of preventive interventions identified some 
preventive interventions that increased 
costs and reduced outcomes as compared to 
the alternative [3].
Budget silo mentality in the decision making 
process also does not aid funding decisions 
about preventive interventions. In Belgium, 
for example, regions are responsible for the 
vaccination budget, whereas national au-
thorities manage the health care budget. This 
means that the costs of implementing a vac-
cination policy are incurred by the regions, 
but the possible health care savings arising 
from the prevention of disease accrue to the 
national budget.
SOCIETAL CONSIDERATIONS
Economic evaluation serves as an instrument 
to maximize population health subject to the 
constraint of limited resources. However, 
cost-effectiveness is only one of the criteria in 
the decision making process, and is probably 
not the most important criterion when focus-
ing on preventive interventions. In addition to 
cost-effectiveness, decision making by policy 
makers may be guided by equity concerns or 
the need to achieve certain targets by means of 
for example public health interventions. This 
is exemplified by the observation that decision 
makers have sometimes funded preventive in-
terventions with high cost-effectiveness ratios 
or refused funding for interventions with low 
cost-effectiveness ratios [7].
One approach to incorporate these societal 
considerations in the decision making process 
is by adapting the threshold value against 
which the incremental cost-effectiveness ra-
tio of an intervention is assessed. This reflects 
the idea that the societal willingness to pay 
for health gain may depend on the type of 
intervention, the type of disease, the percep-
tion of risk, the policy area, etc. For instance, 
the current consultation paper for value-based 
pricing in England and Wales proposes to set 
the threshold value in relation to the innova-
tive character, the disease burden and wider 
societal benefits (e.g. impact on careers) of a 
medicine [8]. Future research needs to elicit 
social values ascribed to preventive interven-
tions with a view to determining the threshold 
value that applies to prevention.
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